MARKET

FTSV

FTSV

Forty Seven
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.79
+0.49
+1.01%
After Hours: 64.75 +15.96 +32.71% 19:58 02/27 EST
OPEN
47.50
PREV CLOSE
48.30
HIGH
51.00
LOW
45.00
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
52.01
52 WEEK LOW
5.53
MARKET CAP
1.45B
P/E (TTM)
-17.5693
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FTSV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FTSV stock price target is 48.00 with a high estimate of 65.00 and a low estimate of 21.00.

EPS

FTSV News

More
  • Trillium +44% after report of possible Forty Seven takeover
  • seekingalpha · 1h ago
  • Biotech company Forty Seven surges 30% after hours on report of Gilead interest
  • MarketWatch · 5h ago
  • Gilead Sciences approaches Forty Seven with takeover deal - Bloomberg
  • Seeking Alpha - Article · 7h ago
  • Forty Seven Shares Spike Sharply Higher After Hours As Hearing Co. Had Discussions About Various Options With Gilead
  • Bloomberg · 9h ago

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.52%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About FTSV

Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
More

Webull offers kinds of Forty Seven Inc stock information, including NASDAQ:FTSV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FTSV stock news, and many more online research tools to help you make informed decisions.